ClinicalTrials.gg
RecruitingNCT05838209Updated Jun 7, 2023

Effect of Ozone Oil After Non-surgical Periodontal Treatment

An interventional study of test and Control in Periodontal Diseases, sponsored by Universidade Federal Fluminense. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-07.

Sponsored by Universidade Federal Fluminense · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Periodontal Diseases with a site in Brazil — 5 open to participants now, 7 under way, 1 of them phase 3. Periodontal Diseases · Brazil.

Planned enrollment
55th of 56
16 · median 43
Started
2023
with 2 others
No phase
39 of 64
2 open now
Registered
51st of 64
by date
Lead sponsor
3 of 64
Universidade Federal Fluminense

Among the 64 studies in Periodontal Diseases with a site in Brazil, this one is the 55th largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2023, is one of 39 with no phase, and was the 51st registered.

Periodontal Diseases

871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.

Browse Periodontal Diseases studies →

Open to participants now

5 of the 64 studies in Periodontal Diseases with a site in Brazil are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Periodontal Diseases with a site in Brazil, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the use of ozone oil as an adjunctive of non-surgical periodontal treatment (NSPT) on diabetics type 2 patients (DM2) compared to control group with chronic periodontal disease.

The principal question is to evaluate if the ozone oil could improve periodontal clinical parameters.

Thirty-two sites of 16 diabetics type 2 patients (DM2) with moderate to advanced periodontal disease containing two sites with periodontal pocket depth (PPD) of > 5 mm were selected.

The treatment was distributed in 2 groups in the split mouth design: Control- scaling and root planing + saline solution (control) and Test - scaling and root planning + ozone oil

03

Conditions studied

  • Periodontal Diseases

Keywords

  • Periodontitis, Periodontal treatment, diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Periodontitis
  • Systemic type 2 diabetes

Exclusion criteria

Exclusion Criteria:

  • to ozone oil
  • Osteoporosis types I and II
  • Alcoholism
  • Immunosuppressio
  • Pregnant and lactating
  • Physical/emotional stress drugs
  • Use of antibiotics, anti-inflammatories and hormone
  • Oral candidiasis
  • Received periodontal treatment in the last six months prior to the procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
16 participants (estimated)

Study arms

  • Placebo comparator
    Control

    Scaling and root planing + saline solution gel (control) will be adminster at probing depth \> 5mm.

    Drug: Control

  • Active comparator
    Test

    Scaling and root planing + Ozone Oil will be adminster at probing depth \> 5mm.

    Drug: test

Interventions

  • Drugtest

    Ozone oil used as an adjunctive of scaling and root planing and control,

  • DrugControl

    saline solution 0.09% used as an adjunctive as scaling and root planing

    Also known as: Placebo Control

06

What researchers measure

Primary outcomes

  1. Plaque Index

    Percentage

    Time frame: baseline

  2. Gingival Index

    Percentage

    Time frame: baseline

  3. Probing Depth

    mm

    Time frame: baseline

  4. clinical attachment level

    mm

    Time frame: baseline

Secondary outcomes

  1. Plaque Index

    Percentage

    Time frame: 3 months

  2. Gingival Index

    Percentage

    Time frame: 3 months

  3. Probing Depth

    mm

    Time frame: 3 months

  4. clinical attachment levels

    mm

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Gabriela Alessandra da Cruz Galhardo Camargo
    Nova Friburgo, RJ 28625650, Brazil
    Recruiting
08

References and documents

Publications

  • Mauri-Obradors E, Merlos A, Estrugo-Devesa A, Jane-Salas E, Lopez-Lopez J, Vinas M. Benefits of non-surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: A randomized controlled trial. J Clin Periodontol. 2018 Mar;45(3):345-353. doi: 10.1111/jcpe.12858. Epub 2018 Jan 19. PubMed 29265454 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2023, 1 month after the start.

Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 1 month is below that.

Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
May 1, 2023
StartActual
Apr 5, 2023
Primary completionEst.
Jun 1, 2023
CompletionEst.
Jul 1, 2023
Last update
Jun 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05838209
Lead sponsor
Universidade Federal Fluminense
Responsible party
Gabriela Alessandra da Cruz Galhardo Camargo (Clinical Professor, Universidade Federal Fluminense) — Principal investigator
First posted
May 1, 2023
Start date
Apr 5, 2023
Primary completion
Jun 1, 2023 (estimated)
Completion
Jul 1, 2023 (estimated)
Last update
Jun 7, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion